Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 2988-2994

  Lempers, V J C ^a   Alffenaar, J W C ^b   Touw, D J ^b,c   Burger, D M ^a   Uges, D R A ^c   Aarnoutse, R E ^a,c   Bruggemann R J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology   (Netherlands)

Author keywords

Analytical method; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; HYDROXYITRACONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; DRUG BLOOD LEVEL; GOOD LABORATORY PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; PLASMA; PRACTICE GUIDELINE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; DRUG MONITORING; INTERNATIONAL COOPERATION; MICROBIAL SENSITIVITY TEST; PROCEDURES; SINGLE BLIND PROCEDURE; STANDARDS; TIME;

ANTIFUNGAL AGENTS; DRUG MONITORING; HUMANS; INTERNATIONALITY; LABORATORY PROFICIENCY TESTING; MICROBIAL SENSITIVITY TESTS; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 84923235532     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku242     Document Type: Article

References (22)

1. Wissen CP, Burger DM, Verweij PE et al. Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 887-888:79-84.
2. Alffenaar JW, Wessels AM, van Hateren K et al. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:39-44.
3. Seyedmousavi S, Mouton JW, Verweij PE et al. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther 2013; 11:931-41.
4. Ashbee HR, Barnes RA, Johnson EM et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69:1162-76.
5. Brüggemann RJ, Donnelly JP, Aarnoutse RE et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30:403-11.
6. Dolton MJ, Ray JE, Marriott D et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:2806-13.
7. Dominguez-Gil HA, Sanchez NA, Garcia Sanchez MJ. Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions. Clin Microbiol Infect 2006; 12 Suppl 7:97-106.
8. Pasqualotto AC, Howard SJ, Moore CB et al. Flucytosine therapeutic monitoring:15 years experience from the UK. J Antimicrob Chemother 2007; 59:791-3.
9. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
10. Miller WG, Jones GR, Horowitz GL et al. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011; 57:1670-80.
11. Brüggemann RJ, Touw DJ, Aarnoutse RE et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009; 53:303-5.
12. Clinical and Laboratory Standards Institute. Using Proficiency Testing to Improve the Clinical Laboratory-Second Edition: Approved Guideline GP27-A2. CLSI, Wayne, PA, USA, 2007.
13. Guidance for Industry: Bioanalytical Method Validation 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (22 May 2014, date last accessed).
14. U.S. Department of Health and Human Services. Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1998 (CLIA): final rule. Federal Register 1992; 57:7002-186.
15. United Kingdom National External Quality Assessment Service (UK NEQAS). Antibiotic Assays. http://www.ukneqas.org.uk/content/Pageserver.asp (22 May 2014, date last accessed).
16. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother 2002; 46:884-6.
17. Burger D, Teulen M, Eerland J et al. The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. Ther Drug Monit 2011; 33:239-43.
18. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24-34.
19. Klee GG, Forsman RW. A user's classification of problems identified by proficiency testing surveys. Arch Pathol Lab Med 1988; 112:371-3.
20. Hoeltge GA, Duckworth JK. Review of proficiency testing performance of laboratories accredited by the College of American Pathologists. Arch Pathol Lab Med 1987; 111:1011-4.
21. Steindel SJ, Howanitz PJ, Renner SWet al. Reasons for proficiency testing failures in clinical chemistry and blood gas analysis: a College of American Pathologists Q-Probes study in 665 laboratories. Arch Pathol Lab Med 1996; 120:1094-101.
22. Jenny RW, Jackson-Tarentino KY. Causes of unsatisfactory performance in proficiency testing. Clin Chem 2000; 46:89-99.